



Prothena Corporation plc  
Investor Relations Department  
331 Oyster Point Blvd  
South San Francisco, CA 94080  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: PRTA

Last Trade:	56.81
Trade Time:	4:00 PM ET Aug 23, 2017
Change:	0.57 <span style="color: green;">↑</span> (+1.014%)
Day Range	55.90 - 57.15
52-Week Range	40.58 - 69.53
Volume	155,211

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Our antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), inflammatory diseases including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004).

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Aug 15, 2017*

[Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting](#)

*Aug 8, 2017*

[Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update](#)

*Aug 1, 2017*

[Prothena to Report Second Quarter 2017 Financial Results on August 8](#)

*Jul 5, 2017*

[Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson's Disease](#)

*Jun 12, 2017*

[Prothena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer](#)

## Financials [\[ View all \]](#)

[Second Quarter Financial Results](#)

*Feb 27, 2017*

[Annual Report \(10-K\)](#)

*Mar 31, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Aug 9, 2017*

[Quarterly Report \(10-Q\)](#)

*May 9, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 2, 2016*

[Quarterly Report \(10-Q\)](#)